•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Sep 04

C&EN News cover story mentions EntreChem glycosylation
engineering technology

  • 4 September, 2006
  • Publications

Professor of biology José Salas and coworkers at the University of Oviedo, Spain, use a different tack. They insert into microorganisms plasmids that endow them with the ability to synthesize novel sugars, which are then transferred to natural products by glycosyltransferases. “Because glycosyltransferases are relatively flexible in their ability to recognize and transfer different sugars, the final result is the generation of novel glycosylated derivatives from a natural product that the microorganism usually synthesizes,” Salas says.

Salas and coworkers recently generated glycosylated derivatives of the protein-kinase inhibitor staurosporine this way and are testing them for inhibitory potency. This technology is also being used by EntreChem, a University of Oviedo spin-off company they founded, to produce anticancer drug candidates.

Read the full article in Chemical & Engineering News
Cover Story – Vol. 84 – N. 36 – Pages 13-22

glycosylation_engineering.pdf (308 KB)

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.